Allergy Therapeutics (AGY.L) Stock Analysis & Winston Score

Allergy Therapeutics is a British pharmaceutical company that makes treatments for allergies. Instead of just treating symptoms, their products work by slowly training the immune system to stop overreacting to things like grass pollen, tree pollen, and house dust mites. Their main customers are allergy clinics and doctors across Europe, and their flagship product line is called Pollinex. The company sells its allergy immunotherapy products primarily in Germany, the UK, and other European markets, generating revenue through direct pharmaceutical sales to healthcare providers. It is a small-cap company with a market cap around $400 million, and its main competitive edge is decades of experience in a niche area of medicine that requires specialized regulatory approvals. However, the company is currently losing money, with a deeply negative operating margin, meaning it spends significantly more than it earns — largely due to ongoing clinical trials and research costs. The key risk is whether it can successfully complete trials and gain broader regulatory approval before running low on funding.